- Kenox Pharmaceuticals Inc. has announced that it is now clinical manufacturing ready and has expanded its GMP analytical testing capabilities for orally inhaled and nasal drug products (OINDPs).
- The CDMO now provides integrated services including development, IVBE testing, and small-scale clinical manufacturing to support Phase I and Phase II trials.
Kenox Pharmaceuticals Inc. has announced that it is now clinical manufacturing ready and has expanded its GMP analytical testing capabilities for orally inhaled and nasal drug products (OINDPs). The company said the upgrades will support innovators developing nasal and inhaled therapies by integrating development, analytical testing, and clinical manufacturing services.
Kenox operates as a contract development and manufacturing organization (CDMO) focused on OINDPs and ophthalmic drug products. The company provides development, GMP testing, and contract manufacturing services designed to support programs progressing toward clinical trials.
“Our goal has always been to help partners reach the clinic faster and with greater confidence.”
Sitaram Velaga, Founder, President, and CEO of Kenox Pharmaceuticals Inc.
Kenox supports small-scale fill–finish operations for small molecules, peptides, and biologics, with batch sizes ranging from hundreds to a few thousand units. According to the company, these capabilities are designed to support Phase I and Phase II clinical studies.
The company’s services include formulation development, analytical testing, in vitro bioequivalence (IVBE) studies, and regulatory support for products such as nebulizers, nasal sprays, soft mist inhalers, and dry powder inhalers. Kenox said these capabilities are intended to provide an integrated development and clinical supply platform for inhaled and nasal drug programs.
